Hemanext
Hemanext is a privately held medical technology company specializing in oxygen-controlled red blood cell processing and storage systems for transfusion medicine. The company develops, manufactures, and commercializes innovative storage solutions that preserve the quality and function of red blood cells by limiting oxygen and carbon dioxide exposure, with the goal of improving transfusion outcomes for patients with chronic and acute conditions. Hemanext's products have received FDA De Novo marketing authorization and CE Mark certification, enabling global distribution. The company is recognized for its focus on scientific evidence, operational compatibility, and strategic partnerships with blood establishments and clinical researchers.
Patents
System for extended storage of red blood cells and methods of use
2025-12-23 • US-12502462-B2
View DetailsMethods for managing adverse events in patients with inflammation
2025-10-21 • US-12447177-B2
View Details
System for extended storage of red blood cells and methods of use
2025-12-23 • US-12502462-B2
View DetailsMethods for managing adverse events in patients with inflammation
2025-10-21 • US-12447177-B2
View DetailsWhat We Do
A medical device system that generates and maintains red blood cells in a low-oxygen, low-carbon dioxide environment for up to 42 days of refrigerated storage, aiming to improve transfusion outcomes by preserving red blood cell quality.
Guidance and technical assistance for adopting hypoxic blood storage solutions into blood center and hospital workflows, including education and troubleshooting.
Customized validation studies, implementation planning, workflow analysis, and training for blood centers to support transition to hypoxic red blood cell processing and storage.
A medical device system that generates and maintains red blood cells in a low-oxygen, low-carbon dioxide environment for up to 42 days of refrigerated storage, aiming to improve transfusion outcomes by preserving red blood cell quality.
Guidance and technical assistance for adopting hypoxic blood storage solutions into blood center and hospital workflows, including education and troubleshooting.
Customized validation studies, implementation planning, workflow analysis, and training for blood centers to support transition to hypoxic red blood cell processing and storage.
Application Area
Battlefield Resuscitation
Regenerative Medicine
Biologics
Digital Health Technologies
Routes of Administration
FDA Regulated Medical Devices
Key People
Andrew Dunham PhD
Chief Executive Officer
Shane Ray
Chief Commercial Officer
Laurel Omert MD
Chief Medical Officer
Suzanna Van Straaten
Head of Global Marketing
Daan Kok
Head of Business Development and Strategy
Andrew Dunham PhD
Chief Executive Officer
Shane Ray
Chief Commercial Officer
Laurel Omert MD
Chief Medical Officer
Suzanna Van Straaten
Head of Global Marketing
Daan Kok
Head of Business Development and Strategy
News & Updates
Received RISE award from the Association for the Advancement of Blood & Biotherapies for research in transfusion medicine.
Recognized by AABB's Standards-Compliant Product Evaluation for quality and safety standards in blood processing and storage.
Peer-reviewed study demonstrates preserved oxygen unloading kinetics in hypoxically stored red blood cells compared to standard storage.
Clinical safety study results on hypoxic red blood cell administration in transfusion-dependent hematological malignancies presented at the European Hematology Association Congress.
Closed Series B-3 funding of $18.9 million at a post-money valuation of $172 million.
Raised just over $20 million in Series B-2 round to fund product implementation and commercial expansion.
Received RISE award from the Association for the Advancement of Blood & Biotherapies for research in transfusion medicine.
Recognized by AABB's Standards-Compliant Product Evaluation for quality and safety standards in blood processing and storage.
Peer-reviewed study demonstrates preserved oxygen unloading kinetics in hypoxically stored red blood cells compared to standard storage.
Clinical safety study results on hypoxic red blood cell administration in transfusion-dependent hematological malignancies presented at the European Hematology Association Congress.
Closed Series B-3 funding of $18.9 million at a post-money valuation of $172 million.
Raised just over $20 million in Series B-2 round to fund product implementation and commercial expansion.